Phenotype anchoring in zebrafish reveals a potential role for matrix metalloproteinases (MMPs) in tamoxifen's effects on skin epithelium.

作者: Sean M Bugel , Leah C Wehmas , Jane K La Du , Robert L Tanguay , None

DOI: 10.1016/J.TAAP.2016.02.013

关键词: Transcription factorGene expressionZebrafishMatrix metalloproteinaseEctopic expressionCell biologyMMP9PhenotypeEndocrinologyInternal medicineCell cycleBiology

摘要: The zebrafish is a powerful alternative model used to link phenotypes with molecular effects discover drug mode of action. Using embryo-larval toxicity bioassay, we evaluated the tamoxifen--a widely anti-estrogen chemotherapeutic. Zebrafish exposed ≥ 10 μM tamoxifen exhibited unique necrotic caudal fin phenotype that was rapidly induced regardless developmental life-stage when treatment applied. To define tamoxifen's bioactivity resulting in this phenotype, targeted gene expression evaluate 100 transcripts involved tissue remodeling, calcium signaling, cell cycle and death, growth factors, angiogenesis hypoxia. most robustly misregulated tail were matrix metalloproteinases mmp9 mmp13a, 127 1145 fold, respectively. Expression c-fos, c-jun, ap1s1 also moderately elevated (3-7 fold), consistent AP-1 activity--a transcription factor regulates MMP expression. Immunohistochemistry confirmed high levels induction for MMP13a affected skin epithelial tissue. significantly attenuated or prevented by three functionally inhibitors: EDTA (metal chelator), GM 6001 (broad inhibitor), SR 11302 (AP-1 suggesting MMP-dependence. inhibited mmp9, putative target, igfbp1a. Overall, our studies suggest effect result perturbation system leading ectopic expression, cytotoxicity, phenotype. These help advance understanding non-classical action implicate possible role MMPs tissues such as skin.

参考文章(74)
Aidas Nasevicius, Stephen C. Ekker, Effective targeted gene ‘knockdown’ in zebrafish Nature Genetics. ,vol. 26, pp. 216- 220 ,(2000) , 10.1038/79951
Kai Kessenbrock, Vicki Plaks, Zena Werb, Matrix Metalloproteinases: Regulators of the Tumor Microenvironment Cell. ,vol. 141, pp. 52- 67 ,(2010) , 10.1016/J.CELL.2010.03.015
T P Barros, W K Alderton, H M Reynolds, A G Roach, S Berghmans, Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery. British Journal of Pharmacology. ,vol. 154, pp. 1400- 1413 ,(2008) , 10.1038/BJP.2008.249
T. Langenegger, P. Wahl, D. Schiesser, B. Thürlimann, Plasma levels of tamoxifen, N-desmethyl tamoxifen and anastrozole in a patient with metastatic breast cancer and chronic hemodialysis. Breast Cancer Research and Treatment. ,vol. 100, pp. 177- 181 ,(2006) , 10.1007/S10549-006-9243-7
Wendy Lorizio, Alan H. B. Wu, Mary S. Beattie, Hope Rugo, Simone Tchu, Karla Kerlikowske, Elad Ziv, Clinical and biomarker predictors of side effects from tamoxifen Breast Cancer Research and Treatment. ,vol. 132, pp. 1107- 1118 ,(2012) , 10.1007/S10549-011-1893-4
Martin Schuler, Ella Bossy-Wetzel, Joshua C. Goldstein, Patrick Fitzgerald, Douglas R. Green, p53 Induces Apoptosis by Caspase Activation through Mitochondrial Cytochrome c Release Journal of Biological Chemistry. ,vol. 275, pp. 7337- 7342 ,(2000) , 10.1074/JBC.275.10.7337
Steven M Harwood, Muhammad M Yaqoob, David A Allen, Caspase and calpain function in cell death: bridging the gap between apoptosis and necrosis Annals of Clinical Biochemistry. ,vol. 42, pp. 415- 431 ,(2005) , 10.1258/000456305774538238
Julie Ducharme, Karen Fried, George Shenouda, Brian Leyland-Jones, Irving W. Wainer, Tamoxifen metabolic patterns within a glioma patient population treated with high‐dose tamoxifen British Journal of Clinical Pharmacology. ,vol. 43, pp. 189- 193 ,(2003) , 10.1046/J.1365-2125.1997.05029.X
Lisa Gallicchio, Gwyn Lord, Katherine Tkaczuk, Malcolm Danton, Lynn M. Lewis, Chang K. Lim, Jodi A. Flaws, Association of Tamoxifen (TAM) and TAM Metabolite Concentrations with Self-Reported Side Effects of TAM in Women with Breast Cancer Breast Cancer Research and Treatment. ,vol. 85, pp. 89- 97 ,(2004) , 10.1023/B:BREA.0000021050.92539.B0